These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 32862147)

  • 21. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
    Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
    Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation.
    Anoshchenko O; Storelli F; Unadkat JD
    Drug Metab Dispos; 2021 Oct; 49(10):919-928. PubMed ID: 34426410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropharmacokinetics of two investigational compounds in rats: divergent temporal profiles in the brain and cerebrospinal fluid.
    Tang C; Chen T; Kapadnis S; Hodgdon H; Tao Y; Chen X; Wen M; Costa D; Murphy D; Nolan S; Flood DG; Welty DF; Koenig G
    Biochem Pharmacol; 2014 Oct; 91(4):543-51. PubMed ID: 25091561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
    Marcelletti JF; Sikic BI; Cripe LD; Paietta E
    Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF as a surrogate for assessing CNS exposure: an industrial perspective.
    Lin JH
    Curr Drug Metab; 2008 Jan; 9(1):46-59. PubMed ID: 18220571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
    Kalvass JC; Maurer TS; Pollack GM
    Drug Metab Dispos; 2007 Apr; 35(4):660-6. PubMed ID: 17237155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
    Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
    Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
    Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
    Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics.
    Shen DD; Artru AA; Adkison KK
    Adv Drug Deliv Rev; 2004 Oct; 56(12):1825-57. PubMed ID: 15381336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
    Karbownik A; Sobańska K; Płotek W; Grabowski T; Klupczynska A; Plewa S; Grześkowiak E; Szałek E
    Invest New Drugs; 2020 Jun; 38(3):574-583. PubMed ID: 31177402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
    Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
    Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.
    Nicolas JM; Chanteux H; Nicolaï J; Brouta F; Viot D; Rosseels ML; Gillent E; Bonnaillie P; Mathy FX; Long J; Helmer E
    Eur J Pharm Sci; 2020 Jan; 142():105122. PubMed ID: 31678424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful Prediction of Fetal Exposure to Dual BCRP/P-gp Drug Substrates Using the Efflux Ratio-Relative Expression Factor Approach and PBPK M&S.
    Balhara A; Yin M; Unadkat JD
    Clin Pharmacol Ther; 2024 May; 115(5):1044-1053. PubMed ID: 38124355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
    Elsby R; Surry DD; Smith VN; Gray AJ
    Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of brain barriers in fluid movement in the CNS: is there a 'glymphatic' system?
    Abbott NJ; Pizzo ME; Preston JE; Janigro D; Thorne RG
    Acta Neuropathol; 2018 Mar; 135(3):387-407. PubMed ID: 29428972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
    Crivori P; Reinach B; Pezzetta D; Poggesi I
    Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
    Doran AC; Osgood SM; Mancuso JY; Shaffer CL
    Drug Metab Dispos; 2012 Nov; 40(11):2162-73. PubMed ID: 22899853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
    Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.